We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Oridis Licenses Tissue Microarray Technology

By Labmedica staff writers
Posted on 05 Dec 2006
Oridis Biomed (Graz, Austria), a biopharmaceutical company, announced that it has entered into a license agreement with the National Institutes of Health (NIH, Bethesda, MD, USA) for the worldwide commercial use of NIH's proprietary tissue microarray (TMA).

TMAs are a tool within Oridis Biomed's Tissomics platform, which permits the rapid and simultaneous study of several hundred tissue samples, using standardized high-throughput analysis by in-house pathologists.

"We are pleased to have been granted by the NIH a license for this TMA technology”, said Georg Casari, Ph.D., head of Oridis Biomed's Tissomics business. More...
"This license agreement further strengthens our Tissomics business for the life-science industry worldwide, where we offer our clients the ability to validate their research, such as biomarker and target verification programs.”

Oridis Biomed commercializes its proprietary Tissomics platform in collaboration with industrial partners, as well as its own research and development programs. The company is developing diagnostics, biomarkers (targeted treatment solutions), and therapeutics for liver diseases. Therapeutic programs include primary liver cancer (hepatocellular carcinoma, HCC) and metabolic liver diseases, such as alcoholic steatohepatitis (ASH) and non- alcoholic steatohepatitis (NASH), where incidence rates are rapidly increasing, while treatment options are limited, expensive, and often ineffective.



Related Links:
Oridis Biomed
National Institutes of Health

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.